Pharmaceuticals
-
Is Pfizer Stock a Buy as COVID Pills Gear Up for Approval?
Pfizer's COVID-19 pill, vaccine and CFO resignation are making headlines this week. Does the news help boost its investment thesis?
-
Open Orphan expands human challenge trial capacity with new volunteer recruitment centres
-
Open Orphan and hVIVO’s human vaccine trial for Covid-19 begins
-
Open Orphan has a great start to 2021 with key 12-month contract renewal
-
Open Orphan wins vaccine contract extension and announces toxicology study completion
-
“We are scaling-up rapidly and at minimum expense” – Open Orphan’s Cathal Friel on the pharma services firm’s exciting plans for 2021 and beyond
-
Open Orphan continues to convert deal pipeline with key Venn contracts
-
Open Orphan strengthens board with Elaine Sullivan hire
-
The second-gen Covid-19 stocks offering explosive opportunities: 4D Pharma
4D Pharma (LSE:DDDD) shares have surged from an all-time low of 23.5p in March to hit as high as 122p in recent days. That’s a share price not seen...
-
Open Orphan lands another £2.5m flu challenge study contract
-
Open Orphan extends pharmacometrics relationship with tier 1 German pharma company
-
Open Orphan reveals transformational Covid-19 vaccine contract with UK government
-
The very first UK online Pharmacy Crowdfund is an opportunity you DO NOT want to miss!
This is the first online Pharmacy crowdfund EVER in the UK and gives investors the opportunity to own a stake in this promising start-up.
-
Open Orphan hits record highs after winning £4.3m vaccine contract
-
Key human challenge expert Adrian Wildfire rejoins hVIVO for Open Orphan boost (ORPH)
-
Omega Diagnostics ramps up Covid-19 antibody tests to 1 million a month, could fly higher (ODX)
